Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies

References

• Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;3–298.
   PubMedGoogle Scholar
• Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA(2)LEN study. Allergy. 2011;66:1216–1223.
   PubMed Web of Science ®Google Scholar
• Soler ZM, Wittenberg E, Schlosser RJ, et al. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121:2672–2678.
   PubMed Web of Science ®Google Scholar
• Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope. 2015;125:1547–1556.
   PubMed Web of Science ®Google Scholar
• Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73:1459–1469.
   PubMed Web of Science ®Google Scholar
• DeConde AS, Soler ZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30:134–139.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and clinical immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131:1479–1490.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, Scadding GK. Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches. Allergy Asthma Immunol Res. 2011;3:226–235.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, Rotiroti G. Allergic rhinitis, chronic rhinosinusitis and asthma: unravelling a complex relationship. Curr Opin Otolaryngol Head Neck Surg. 2013;21:79–86.
   PubMed Web of Science ®Google Scholar
• Bhimrao SK, Wilson SJ, Howarth PH. Airway inflammation in atopic patients: a comparison of the upper and lower airways. Otolaryngol Head Neck Surg. 2011;145:396–400.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Overbeek SE, Kleinjan A, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107:469–476.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000;161:2051–2057.
   PubMed Web of Science ®Google Scholar
• Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–98.
   PubMed Web of Science ®Google Scholar
• Bresciani M, Paradis L, Des RA, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107:73–80.
   PubMed Web of Science ®Google Scholar
• Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12:272–276.
   PubMed Web of Science ®Google Scholar
• Bidder T, Sahota J, Rennie C, et al. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology. 2018;56:42–45.
   PubMed Web of Science ®Google Scholar
• Wei B, Liu F, Zhang J, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018;56(3):216–226.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607–614.
   PubMed Web of Science ®Google Scholar
• Samitas K, Carter A, Kariyawasam HH, et al. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy. 2018;73:993–1002.
   PubMed Web of Science ®Google Scholar
• Van Lancker JA, Yarnold PA, Ditto AM, et al. Aeroallergen hypersensitivity: comparing patients with nasal polyps to those with allergic rhinitis. Allergy Asthma Proc. 2005;26:109–112.
   PubMed Web of Science ®Google Scholar
• Chang EH, Stern DA, Willis AL, et al. Early life risk factors for chronic sinusitis: A longitudinal birth cohort study. J Allergy Clin Immunol. 2018;141:1291–1297.e1292.
   PubMedGoogle Scholar
• Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol. 1977;59:17–21.
   PubMed Web of Science ®Google Scholar
• Bunnag C, Pacharee P, Vipulakom P, et al. A study of allergic factor in nasal polyp patients. Ann Allergy. 1983;50:126–132.
   PubMedGoogle Scholar
• Johansson L, Akerlund A, Holmberg K, et al. Prevalence of nasal polyps in adults: the Skovde population-based study. Ann Otol Rhinol Laryngol. 2003;112:625–629.
   PubMed Web of Science ®Google Scholar
• Stentzel S, Teufelberger A, Nordengrun M, et al. Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J Allergy Clin Immunol. 2017;139:492–500.e498.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, van Cauwenberge P. Staphylococcus aureus superantigens and airway disease. Curr Allergy Asthma Rep. 2002;2:252–258.
   PubMedGoogle Scholar
• Chen JB, James LK, Davies AM, et al. Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;139:1195–1204.e1111.
   PubMed Web of Science ®Google Scholar
• Milonski J, Zielinska-Blizniewska H, Majsterek I, et al. Expression of POSTN, IL-4, and IL-13 in Chronic rhinosinusitis with nasal polyps. DNA Cell Biol. 2015;34:342–349.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Nouri-Aria KT, Wu H, et al. Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy. 2013;68:55–63.
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Le Gros G, Bertrand C, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995;13:54–59.
   PubMed Web of Science ®Google Scholar
• Hogan SP, Matthaei KI, Young JM, et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol. 1998;161:1501–1509.
   PubMed Web of Science ®Google Scholar
• Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol. 1998;161:3813–3816.
   PubMed Web of Science ®Google Scholar
• Gavett SH, O’Hearn DJ, Karp CL, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 1997;272:L253–261.
   PubMed Web of Science ®Google Scholar
• Kuperman D, Schofield B, Wills-Karp M, et al. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med. 1998;187:939–948.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–2261.
   PubMed Web of Science ®Google Scholar
• Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261–2263.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–788.
   PubMed Web of Science ®Google Scholar
• McKenzie DT, Filutowicz HI, Swain SL, et al. Purification and partial sequence analysis of murine B cell growth factor II (interleukin 5). J Immunol. 1987;139:2661–2668.
   PubMed Web of Science ®Google Scholar
• Baumann MA, Paul CC. Interleukin-5 and human B lymphocytes. Methods. 1997;11:88–97.
   PubMed Web of Science ®Google Scholar
• Denburg JA, Silver JE, Abrams JS. Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood. 1991;77:1462–1468.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, Robinson DS. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med. 2006;27:117–127.
   PubMed Web of Science ®Google Scholar
• Stoeckle C, Simon HU. CD8(+) T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases. Allergy. 2013;68:1622–1625.
   PubMed Web of Science ®Google Scholar
• Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013;502:245–248.
   PubMed Web of Science ®Google Scholar
• Paul CC, Keller JR, Armpriester JM, et al. Epstein-Barr virus transformed B lymphocytes produce interleukin-5. Blood. 1990;75:1400–1403.
   PubMed Web of Science ®Google Scholar
• Plaut M, Pierce JH, Watson CJ, et al. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature. 1989;339:64–67.
   PubMed Web of Science ®Google Scholar
• Salvi S, Semper A, Blomberg A, et al. Interleukin-5 production by human airway epithelial cells. Am J Respir Cell Mol Biol. 1999;20:984–991.
   PubMed Web of Science ®Google Scholar
• Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994;179:703–708.
   PubMed Web of Science ®Google Scholar
• Milburn MV, Hassell AM, Lambert MH, et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363:172–176.
   PubMed Web of Science ®Google Scholar
• Rossjohn J, McKinstry WJ, Woodcock JM, et al. Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist. Blood. 2000;95:2491–2498.
   PubMed Web of Science ®Google Scholar
• Pazdrak K, Stafford S, Alam R. The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils. J Immunol. 1995;155:397–402.
   PubMed Web of Science ®Google Scholar
• Stout BA, Bates ME, Liu LY, et al. IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils. J Immunol. 2004;173:6409–6417.
   PubMed Web of Science ®Google Scholar
• Pazdrak K, Olszewska-Pazdrak B, Stafford S, et al. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med. 1998;188:421–429.
   PubMed Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis. 2017;5:233–243.
   PubMed Web of Science ®Google Scholar
• Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12:1055–1062.
   PubMed Web of Science ®Google Scholar
• Camelo A, Rosignoli G, Ohne Y, et al. IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells. Blood Adv. 2017;1:577–589.
   PubMed Web of Science ®Google Scholar
• Liao B, Cao PP, Zeng M, et al. Interaction of thymic stromal lymphopoietin, IL-33, and their receptors in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. Allergy. 2015;70:1169–1180.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1566–1576.e1565.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–680.
   PubMed Web of Science ®Google Scholar
• Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202:1213–1223.
   PubMed Web of Science ®Google Scholar
• Wong CK, Hu S, Cheung PF, et al. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010;43:305–315.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253–258.
   PubMed Web of Science ®Google Scholar
• Lei L, Zhang Y, Yao W, et al. Thymic stromal lymphopoietin interferes with airway tolerance by suppressing the generation of antigen-specific regulatory T cells. J Immunol. 2011;186:2254–2261.
   PubMed Web of Science ®Google Scholar
• Shin HW, Kim DK, Park MH, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015;135:1476–1485.e1477.
   PubMed Web of Science ®Google Scholar
• Lam EP, Kariyawasam HH, Rana BM, et al. IL-25/IL-33-responsive T2 cells characterize nasal polyps with a default T17 signature in nasal mucosa. J Allergy Clin Immunol. 2016;137(5):1514–1524.
   Web of Science ®Google Scholar
• Suzukawa M, Morita H, Nambu A, et al. Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma. J Immunol. 2012;189:3641–3652.
   PubMed Web of Science ®Google Scholar
• Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985–995.
   PubMed Web of Science ®Google Scholar
• Angkasekwinai P, Chang SH, Thapa M, et al. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol. 2010;11:250–256.
   PubMed Web of Science ®Google Scholar
• Temann UA, Geba GP, Rankin JA, et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188:1307–1320.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang LL, Cao ZW. Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-kappaB signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21:4501–4508.
   PubMed Web of Science ®Google Scholar
• Shaw JL, Fakhri S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med. 2013;188:432–439.
   PubMed Web of Science ®Google Scholar
• Kim DK, Jin HR, Eun KM, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72:635–645.
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Frigas E, Loegering DA, et al. Cytotoxic properties of the eosinophil major basic protein. J Immunol. 1979;123:2925–2927.
   PubMed Web of Science ®Google Scholar
• O’Donnell MC, Ackerman SJ, Gleich GJ, et al. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med. 1983;157:1981–1991.
   PubMed Web of Science ®Google Scholar
• Moy JN, Gleich GJ, Thomas LL. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol. 1990;145:2626–2632.
   PubMed Web of Science ®Google Scholar
• Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101:834–846.
   PubMed Web of Science ®Google Scholar
• Powell PP, Klagsbrun M, Abraham JA, et al. Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension. Am J Pathol. 1993;143:784–793.
   PubMed Web of Science ®Google Scholar
• Wong DT, Donoff RB, Yang J, et al. Sequential expression of transforming growth factors alpha and beta 1 by eosinophils during cutaneous wound healing in the hamster. Am J Pathol. 1993;143:130–142.
   PubMed Web of Science ®Google Scholar
• Wong DT, Elovic A, Matossian K, et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood. 1991;78:2702–2707.
   PubMed Web of Science ®Google Scholar
• Balzar S, Chu HW, Silkoff P, et al. Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol. 2005;115:110–117.
   PubMed Web of Science ®Google Scholar
• Moqbel R, Ying S, Barkans J, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol. 1995;155:4939–4947.
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002;169:1021–1027.
   PubMed Web of Science ®Google Scholar
• Haughney J, Morice A, Blyth KG, et al. A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med. 2018;134:117–123.
   PubMed Web of Science ®Google Scholar
• Wright JD, Chu HM, Huang CH, et al. Structural and physical basis for anti-IgE therapy. Sci Rep. 2015;5:11581.
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–340.
   PubMed Web of Science ®Google Scholar
• Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48:1593–1601.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Kariyawasam HH, Heaney LG. Phase three studies of biologics for severe asthma: could do better? Eur Respir J. 2017;50(3). pii: 1701108. doi:10.1183/13993003.01108-2017.
   Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–116.
   PubMed Web of Science ®Google Scholar
• Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318–324.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824–825.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Hiraumi H, et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol. 2013;110:387–388.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5). pii: 1702523. doi:10.1183/13993003.02523-2017.
   Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosen K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73:490–497.
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449–1456.e1444.
   PubMed Web of Science ®Google Scholar
• Huang YC, Weng CM, Lee MJ, et al. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy. Clin Exp Allergy. 2018. doi:10.1111/cea.13248 [Epub ahead of print].
   Google Scholar
• Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49:779–790.
   PubMed Web of Science ®Google Scholar
• Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50:215–227.
   PubMed Web of Science ®Google Scholar
• Kaufman MB. Pharmaceutical approval update. P T. 2018;43:22–60.
   PubMedGoogle Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353.e1342.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133–1141.
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Germinaro M, Bardin P, et al. Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils. J Allergy Clin Immunol. 2016;137:AB86.
   Web of Science ®Google Scholar
• Mj L, Ten BA, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144–2148.
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Kariyawasam HH. Mepolizumab for eosinophilic severe asthma: recent studies. Expert Opin Biol Ther. 2015;15:909–914.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van BN, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128:989–995.
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024–1031.
   PubMed Web of Science ®Google Scholar
• Gregory B, Kirchem A, Phipps S, et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol. 2003;170:5359–5366.
   PubMed Web of Science ®Google Scholar
• Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol. 2002;169:6452–6458.
   PubMed Web of Science ®Google Scholar
• Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol. 2002;169:6459–6466.
   PubMed Web of Science ®Google Scholar
• Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121:1473–1483, 1483.e1471–1474.
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, McKenna S, et al. Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy. 2005;35:598–601.
   PubMed Web of Science ®Google Scholar
• Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53:1015–1027.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029–1036.
   PubMed Web of Science ®Google Scholar
• Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med. 2017;196:1385–1395.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–1932.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51–64.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315:469–479.
   PubMed Web of Science ®Google Scholar
• Toma S, Hopkins C. Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments. Rhinology. 2016;54:129–133.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–946.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294–1302.
   PubMed Web of Science ®Google Scholar
• Takaku Y, Soma T, Nishihara F, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol. 2013;161(Suppl 2):107–117.
   PubMed Web of Science ®Google Scholar
• Skiepko R, Zietkowski Z, Lukaszyk M, et al. Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation. Postepy Dermatol Alergol. 2014;31:305–309.
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117:1493–1499.
   PubMed Web of Science ®Google Scholar
• van Rensen EL, Evertse CE, van Schadewijk WA, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64:72–80.
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–593.
   PubMed Web of Science ®Google Scholar
• Gomez G, Jogie-Brahim S, Shima M, et al. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol. 2007;179:1353–1361.
   PubMed Web of Science ®Google Scholar
• Shimokawa C, Kanaya T, Hachisuka M, et al. Mast cells are crucial for induction of group 2 innate lymphoid cells and clearance of helminth infections. Immunity. 2017;46:863–874.e864.
   PubMed Web of Science ®Google Scholar
• Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141:1735–1743.e1739.
   PubMed Web of Science ®Google Scholar
• Golebski K, van Tongeren J, van Egmond D, et al. Specific Induction of TSLP by the viral RNA analogue poly(I:C) in primary epithelial cells derived from nasal polyps. PLoS One. 2016;11:e0152808.
   PubMed Web of Science ®Google Scholar
• Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg-Strauss syndrome–a serum marker closely correlating with disease activity. Rheumatology (Oxford). 2008;47:804–808.
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5:1362–1370.e1362.
   PubMed Web of Science ®Google Scholar
• Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006;118:128–133.
   PubMed Web of Science ®Google Scholar
• Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069–1076.
   PubMed Web of Science ®Google Scholar
• Godar M, Deswarte K, Vergote K, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. 2018;142:1185–1193.
   PubMed Web of Science ®Google Scholar